Virtus ETF Advisers LLC Incyte Corp Transaction History

Virtus ETF Advisers LLC

$206 Million
Q3 2024

A detailed history of Virtus ETF Advisers LLC transactions in Incyte Corp stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 5,254 shares of INCY stock, worth $380,442. This represents 0.17% of its overall portfolio holdings.

Number of Shares

5,254

Previous 5,254 -0.0%

Holding current value

$380,442

Previous $318,000 9.12%

% of portfolio

0.17%

Previous 0.16%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$51.18 - $63.75 $36,593 - $45,581	-715 Reduced 11.98%	5,254 $318,000
Q1 2024 May 15, 2024	BUY	$56.55 - $66.59 $48,576 - $57,200	859 Added 16.81%	5,969 $340,000
Q4 2023 Feb 15, 2024	BUY	$52.16 - $64.19 $8,293 - $10,206	159 Added 3.21%	5,110 $320,000
Q3 2023 Nov 07, 2023	SELL	$57.77 - $65.93 $642,055 - $732,746	-11,114 Reduced 69.18%	4,951 $286,000
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $104,102 - $128,971	1,708 Added 11.9%	16,065 $1 Million
Q1 2023 May 15, 2023	SELL	$70.23 - $86.01 $17,557 - $21,502	-250 Reduced 1.71%	14,357 $1.04 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $191,530 - $239,797	2,851 Added 24.25%	14,607 $1.17 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $545,985 - $683,595	8,250 Added 235.31%	11,756 $783,000
Q2 2022 Aug 12, 2022	SELL	$66.18 - $83.18 $126,867 - $159,456	-1,917 Reduced 35.35%	3,506 $266,000
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $7,157 - $8,374	-113 Reduced 2.04%	5,423 $398,000
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $34,747 - $42,514	-506 Reduced 8.37%	5,536 $381,000
Q2 2021 Aug 10, 2021	SELL	$79.87 - $87.53 $92,808 - $101,709	-1,162 Reduced 16.13%	6,042 $508,000
Q1 2021 May 17, 2021	BUY	$76.02 - $100.5 $14,671 - $19,396	193 Added 2.75%	7,204 $585,000
Q4 2020 Feb 12, 2021	BUY	$80.74 - $97.7 $53,530 - $64,775	663 Added 10.44%	7,011 $610,000
Q3 2020 Nov 13, 2020	BUY	$85.07 - $109.69 $45,512 - $58,684	535 Added 9.2%	6,348 $570,000
Q2 2020 Aug 05, 2020	SELL	$74.18 - $108.93 $45,323 - $66,556	-611 Reduced 9.51%	5,813 $604,000
Q1 2020 May 14, 2020	SELL	$63.18 - $85.97 $34,306 - $46,681	-543 Reduced 7.79%	6,424 $470,000
Q4 2019 Feb 13, 2020	SELL	$73.04 - $95.72 $141,989 - $186,079	-1,944 Reduced 21.82%	6,967 $608,000
Q3 2019 Nov 12, 2019	SELL	$72.82 - $86.52 $109,666 - $130,299	-1,506 Reduced 14.46%	8,911 $661,000
Q2 2019 Aug 13, 2019	SELL	$73.52 - $88.7 $80,577 - $97,215	-1,096 Reduced 9.52%	10,417 $885,000
Q1 2019 May 14, 2019	BUY	$63.56 - $88.17 $155,086 - $215,134	2,440 Added 26.89%	11,513 $990,000
Q4 2018 Feb 05, 2019	BUY	$58.5 - $69.94 $487,363 - $582,670	8,331 Added 1122.78%	9,073 $577,000
Q3 2018 Nov 14, 2018	SELL	$61.75 - $74.23 $573,163 - $689,002	-9,282 Reduced 92.6%	742 $742,000
Q2 2018 Aug 10, 2018	BUY	$60.85 - $83.98 $29,633 - $40,898	487 Added 5.11%	10,024 $671,000
Q1 2018 May 14, 2018	SELL	$83.06 - $100.98 $55,484 - $67,454	-668 Reduced 6.55%	9,537 $795,000
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $148,386 - $184,927	1,586 Added 18.4%	10,205 $967,000
Q2 2017 Aug 14, 2017	BUY	N/A	8,619	8,619 $1.09 Million

Others Institutions Holding INCY

# of Institutions

651

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account

Virtus ETF Advisers LLC Incyte Corp Transaction History